Lantern Pharma Inc. (LTRN) - Q1 2025 10-Q Summary
Business Context and Reporting Period
Lantern Pharma Inc. is an artificial intelligence-focused biopharmaceutical company developing oncology therapies. The company utilizes its proprietary RADR® platform to identify drug candidates and patient populations. The reporting period covers the three months ended March 31, 2025. The company operates as a single segment and is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,536,783) | $(5,440,810) |
| Loss Per Share (Basic & Diluted) | $(0.42) | $(0.51) |
| Total Operating Expenses | $4,774,032 | $5,732,001 |
| Research & Development (R&D) | $3,263,955 | $4,250,786 |
| General & Administrative (G&A) | $1,510,077 | $1,481,215 |
| Cash and Cash Equivalents | $6,377,602 | $18,357,944 |
| Marketable Securities | $13,344,049 | $16,501,984 |
| Total Assets | $21,096,335 | $25,571,792 |
| Working Capital | $16,536,942 | $20,916,454 |
| Long-Term Debt | $0 | $0 |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $904,000 (17%) compared to Q1 2024, primarily driven by a $987,000 reduction in R&D expenses.
- R&D Expense Decline: R&D expenses dropped 23% to $3.26 million. This was largely due to a $963,000 decrease in research services, specifically reductions in contract research organization (CRO) and clinical site costs for the LP-184 program.
- G&A Expense Increase: G&A expenses increased slightly by 2% to $1.51 million, attributed to higher professional fees ($133,000) and salaries ($34,000), partially offset by lower business development costs.
- Cash Position: Cash and cash equivalents decreased by $1.13 million during the quarter. Total liquid assets (cash plus marketable securities) stood at approximately $19.7 million as of March 31, 2025.
- Investing Activities: The company generated $3.24 million in net cash from investing activities, primarily due to the redemption of marketable securities ($8.22 million) exceeding purchases ($4.98 million).
Outlook, Risks, and Management Commentary
- Liquidity and Capital Needs: Management believes existing cash, cash equivalents, and marketable securities will fund operations for at least 12 months from the filing date. However, the company expects to incur significant losses for the foreseeable future and will require substantial additional funding to complete clinical trials.
- Clinical Pipeline:
- LP-300: Advancing in a Phase 2 trial (Harmonic™) for never-smokers with advanced non-small cell lung cancer (NSCLC).
- LP-184 (STAR-001): Advancing in a Phase 1 trial for solid tumors and CNS cancers (via subsidiary Starlight Therapeutics).
- LP-284: Advancing in a Phase 1 trial for hematological cancers.
- ADC Program: Preclinical optimization of antibody-drug conjugates using cryptophycins.
- Risks: Key risks include the inability to raise capital, which could force delays or elimination of drug programs; failure of clinical trials; reliance on third-party manufacturers; and potential impacts of trade policies and tariffs on operating expenses.
- Unusual Items: The company recorded a realized loss of $142,248 on the redemption of equity securities and an unrealized gain of $151,264 on equity securities during the quarter.
Investor Verification Checklist
- Cash Runway: Verify the 12-month liquidity projection against current burn rates and potential capital raise timelines.
- LP-300 Trial Status: Confirm enrollment progress and data readout timelines for the Harmonic™ Phase 2 trial in NSCLC.
- LP-184 Cost Reductions: Assess the impact of reduced CRO spending on the timeline for the LP-184 Phase 1 trial.
- Starlight Therapeutics: Review the specific strategic focus and resource allocation for the CNS/brain cancer subsidiary.
- Market Risk: Evaluate the exposure of the $13.3 million marketable securities portfolio to interest rate fluctuations and credit risk.